Cellectis SA
(FRA:ZVAA)
€
1.81
-0.02 (-1.09%)
Market Cap: 181.16 Mil
Enterprise Value: 130.60 Mil
PE Ratio: 0
PB Ratio: 1.59
GF Score: 50/100 - Q1 2024 Cellectis SA Earnings Call TranscriptMay 29, 2024€2.52 (-1.56%)Earnings
- Q3 2023 Cellectis SA Earnings Call TranscriptNov 07, 2023€2.08 (-17.46%)Earnings
- Cellectis SA at Jefferies Cell & Genetic Medicine Summit TranscriptSep 26, 2023
- Q2 2023 Cellectis SA Earnings Call TranscriptAug 04, 2023€1.71 (+1.79%)Earnings
- Cellectis SA at Goldman Sachs Healthcare Conference TranscriptJun 15, 2023
- Q1 2023 Cellectis SA Earnings Call TranscriptMay 05, 2023€1.63 (+1.24%)Earnings
- Cellectis SA at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Cellectis SA Earnings Call TranscriptMar 09, 2023€1.95Earnings
- Cellectis SA Corporate Analyst Meeting (Virtual) TranscriptDec 13, 2022
- Q3 2022 Cellectis SA Earnings Call TranscriptNov 04, 2022€2.38 (-3.25%)Earnings
- Atara Biotherapeutics Inc, Cellectis SA and 2Seventy Bio Inc at Citi BioPharma Conference- Panel TranscriptSep 07, 2022
- Q2 2022 Cellectis SA Earnings Call TranscriptAug 05, 2022€2.92 (-5.81%)Earnings
- Cellectis SA at Goldman Sachs Global Healthcare Conference TranscriptJun 16, 2022
- Cellectis SA at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Cellectis SA Earnings Call TranscriptMay 13, 2022€2.84 (+9.23%)Earnings
- Cellectis SA at Barclays Global Healthcare Conference TranscriptMar 17, 2022
- Q4 2021 Cellectis SA Earnings Call TranscriptMar 04, 2022€3.32 (-6.74%)Earnings
- Cellectis SA at Barclays Gene Editing & Gene Therapy Summit (Virtual) TranscriptNov 15, 2021
- Q3 2021 Cellectis SA Earnings Call TranscriptNov 05, 2021€10.5 (-1.87%)Earnings
- Cellectis SA at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Cellectis SA Earnings Call TranscriptAug 06, 2021€11.3 (+3.67%)Earnings
- Cellectis SA at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Q4 2020 Cellectis SA Earnings Call TranscriptMar 05, 2021€15.8 (-3.07%)Earnings
- Cellectis SA at Barclays Virtual Gene Editing & Gene Therapy Summit - Presentation TranscriptNov 16, 2020
- Q3 2020 Cellectis SA Earnings Call TranscriptNov 06, 2020€15.1 (+8.63%)Earnings
- Cellectis SA at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Q2 2020 Cellectis SA Earnings Call TranscriptAug 06, 2020€14.8 (+2.78%)Earnings
- Cellectis SA Chardan Leadership Call TranscriptMay 27, 2020
- Q1 2020 Cellectis SA Earnings Call TranscriptMay 07, 2020€12.8 (-1.54%)Earnings
- Q4 2019 Cellectis SA Earnings Call TranscriptMar 05, 2020€14Earnings
- Q3 2019 Cellectis SA Earnings Call TranscriptNov 07, 2019€11.3 (+2.73%)Earnings
- Cellectis SA at Citi Biotech Conference TranscriptSep 04, 2019
- Cellectis SA at Goldman Sachs Global Healthcare Conference TranscriptJun 13, 2019
- Cellectis SA at Barclays Global Healthcare Conference TranscriptMar 13, 2019
- Q4 2018 Cellectis SA Earnings Call TranscriptMar 12, 2019€16.1 (+1.26%)Earnings
Cellectis SA at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022 / 05:00PM GMT
Release Date Price:
€2.26
(+2.73%)
Matthew (Trades, Portfolio)atorre
Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, everyone, and thank you for joining us for Day 4 of the Goldman Sachs Healthcare Conference. We're really pleased to have Cellectis here. And with us, we have Bing Wang, CFO. So just to get started. So Cellectis is a clinical-stage biotech company using its platform to develop cell therapies.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)